RxDoctor Payments Data

Marilyn Salada Ligon, MD

Family Medicine · Madison, ALNPI 1740481951

Payments from drug & device makers

$2,417in general payments, 2019–2025

Across 134 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$309
  • Amgen$251
  • Astellas Pharma US Inc$215
  • UCB, Inc.$212
  • Novartis$180
  • Pfizer$163
  • plus $1K from 31 others

What the payments were for

  • Food & beverage$2,23793%
  • Education$1807%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,417 in reported general payments places this provider in the 70th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$68,463
Medicare patients
362
Services billed
1,071

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban537$231,086
JardianceEmpagliflozin193$87,281
MounjaroTirzepatide33$39,252
XareltoRivaroxaban83$37,141
JanuviaSitagliptin Phosphate72$34,705
FarxigaDapagliflozin Propanediol53$27,588
EntrestoSacubitril/Valsartan45$27,034
OzempicSemaglutide23$26,063
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$21,066
MyrbetriqMirabegron54$20,038
ZenpepLipase/Protease/Amylase12$18,675
NamzaricMemantine Hcl/Donepezil Hcl24$15,464
Atorvastatin Calcium776$12,716
RexultiBrexpiprazole16$12,587
NeuproRotigotine12$10,464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$163$231,086537 claims
Lilly USA, LLCMounjaro$33$39,25233 claims
MerckJanuvia$36$34,70572 claims
AstraZenecaFarxiga$15$27,58853 claims
NovartisEntresto$180$27,03445 claims
GSKTrelegy Ellipta, Breo Ellipta$38$26,43841 claims
Novo NordiskOzempic$79$26,06323 claims
Astellas Pharma US IncMyrbetriq$215$20,03854 claims
UCB, Inc.Neupro, Briviact$212$15,85526 claims
AbbVieNamzaric$309$15,46424 claims
Otsuka America Pharmaceutical, Inc.Rexulti$51$12,58716 claims
Sanofi-aventis U.S. LLCLantus$47$5,57258 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Madison

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →